Drug intelligence / Profile preview

IQP-AK-102

Development stage
Unknown
Lead developer
InQpharm
Administration
Oral
01

Overview

IQP-AK-102 (Redusure) is a proprietary, patent-pending composition of three soluble dietary fibers: purified glucomannan (derived from the tuberous roots of *Amorphophallus konjac*), kappa-carrageenan, and xanthan gum. Developed by InQpharm, it is intended for weight management in overweight and obese individuals. The mechanism of action involves the synergistic interaction of these high-molecular-weight polysaccharides to form a thick, highly viscous, and indigestible gel structure in the stomach upon contact with water. This gel increases gastric distension and delays gastric emptying, thereby enhancing the sensation of satiety and reducing subsequent energy intake. Clinical studies, including a 12-week randomized, double-blind, placebo-controlled trial (NCT01905956), have demonstrated that IQP-AK-102 supplementation, in conjunction with a mildly hypocaloric diet and regular physical activity, promotes significant reductions in body weight, body fat mass, and waist circumference compared to placebo.

Brand names
Redusure
Other names
Redusure IQP-AK-102

Beyond the preview

Go deeper on IQP-AK-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IQP-AK-102.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call